FREE Account Opening + No Clearing Fees

Aristo Bio-Tech NSE SME IPO Review (May apply)

Review By Dilip Davda on January 10, 2023

•    ABLL is engaged in the manufacturing and marketing of agrochemicals.
•    Though it suffered a setback in its top lines for FY21 and FY22, it earned higher profits.
•    Based on its recent financials, the issue appears fully priced. 
•    As the segment is getting crowded, margin sustainability is a major concern.
•    Well-informed investors may consider it for long-term rewards.

Aristo Bio-Tech and Lifescience Ltd. (ABLL) is an agrochemical company engaged in the manufacturing, formulation, supplying, packaging, and job work services in various Pesticides such as Insecticides, Herbicides, Fungicides, Plant Growth Regulators, and a wide variety of other Agrochemicals for India as well as for Export. 

Agrochemical industries are very vast fields and deal with the production and distribution of pesticides and fertilizers to increase crop yields. Agrochemicals (Crop protection products/pesticides) are designed to protect crops from insects, diseases, and weeds. Currently, the company has 182 products registered with CIB&RC for manufacturing and sales.

ABLL supplies its products across 20 states i.e. Assam, Andhra Pradesh, Bihar, Chhattisgarh, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttarakhand, Uttar Pradesh, West Bengal, and 15 Countries i.e. Armenia, Australia, Bangladesh, Belgium, Cambodia, Germany, Italy, Kenya, Moldova, New Zealand, Poland, South Africa, UAE, Ukraine, and Vietnam.

The Company manufactures agrochemicals such as Insecticides, Herbicides, Fungicides, and Plant Growth Regulators which are directly sold to customers, and is also engaged in Job work as per customer requirements. As of September 30, 2022, the Company has 55 employees on the payroll.

It has also entered into agreements with some of the parties to undertake the marketing of products produced by the company on the terms & conditions as discussed mutually. The products are marketed by the brand names of the respective parties.

The company is coming out with its maiden IPO of 1812800 equity shares of Rs. 10 each at a fixed price of Rs. 72 per share to mobilize Rs. 13.05 cr. The issue opens for subscription on January 16, 2023, and will close on January 19, 2023. The minimum application to be made is for 1600 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 26.63% of the post-issue paid-up capital of the company. ABLL is spending Rs. 1.20 cr. for this IPO process and from the net proceeds, it will use Rs. 9.35 cr. for working capital and Rs. 2.50 cr. for general corporate purposes. 

Beeline Capital Advisors Pvt. Ltd. is the sole lead manager for this issue and Link Intime India Pvt. Ltd. is the registrar of the issue.  Sunflower Broking Pvt. Ltd. is the market maker for this company.
The company has after issuing initial equity shares at par, issued further equity shares at a fixed price of Rs. 15 per share in March 2012. It has also issued bonus shares in the ratio of 4 for 1 in September 2018. The average cost of acquisition of shares by the promoters is Rs. 2.12, Rs.  2.16, and Rs. 3.00 per share. 

Post-IPO, ABLL's current paid-up equity capital of Rs. 5.00 cr. will stand enhanced to Rs. 6.81 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 49.02 cr. 

On the financial performance front, for the last three fiscals, ABLL has posted a turnover/net profit of Rs. 201.24 cr. / Rs. 1.01 cr. (FY20), Rs. 167.23 cr. / Rs. 1.08 cr. (FY21), and Rs. 166.03 cr. / Rs. 1.46 cr. (FY22). For H1 of FY23 ended on September 30, 2022, it earned a net profit of Rs. 2.59 cr. on a turnover of Rs. 129.07 cr. The sudden boost in the net profits for the last 18 months raises eyebrows. 

For the last three fiscals, ABLL has reported an average EPS of Rs. 2.52 and an average RoNW of 9.05%. The issue is priced at a P/BV of 2.06 based on its NAV of Rs. 34.90 as of September 30, 2022, and at a P/BV of 1.67 based on its post-IPO NAV of Rs. 43.01 per share. 

If we annualize FY23 super earnings and attribute it to post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of around 9.46. Thus the issue appears fully priced. 

The company has not declared any dividends in the last five fiscals. It will adopt a prudent dividend policy post-listing based on its financial performance and future prospects. 

As per the offer document, ABLL has shown Dhanuka Agritech and Meghmani Organics as their listed peers. They are currently trading at a P/E of 15.58 and 7.65 (as of January 10, 2023). However, they are not truly comparable on an apple-to-apple basis. 

This is the 7th mandate from Beeline Capital in the current fiscal. Out of the last 6 listings, 1 opened at par and the rest with premiums ranging from 3.96% to 63.64% on the day of listing.

Conclusion / Investment Strategy

Based on its super earnings for H1 of FY23, the IPO is fully priced discounting all near-term positives. The sustainability of such margins going forward is a major concern. The segment too is becoming crowded and highly competitive. Post-IPO small paid-up equity also indicates longer gestation for migration to the main board. Well-informed investors may park funds with a long-term perspective.

Review By Dilip Davda on January 10, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Aristo Bio-Tech and Lifescience IPO FAQs

  1. 1. Why Aristo Bio-Tech and Lifescience IPO?

    The initial public offer (IPO) of Aristo Bio-Tech and Lifescience Limited offers an early investment opportunity in Aristo Bio-Tech and Lifescience Limited. A stock market investor can buy Aristo Bio-Tech and Lifescience IPO shares by applying in IPO before Aristo Bio-Tech and Lifescience Limited shares get listed at the stock exchanges. An investor could invest in Aristo Bio-Tech and Lifescience IPO for short term listing gain or a long term.

  2. 2. How is Aristo Bio-Tech and Lifescience IPO?

    Read the Aristo Bio-Tech and Lifescience IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Aristo Bio-Tech and Lifescience IPO what should investors do?

    Aristo Bio-Tech and Lifescience IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Aristo Bio-Tech and Lifescience IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Aristo Bio-Tech and Lifescience IPO good?

    Our recommendation for Aristo Bio-Tech and Lifescience IPO is to subscribe for long term.

  5. 5. Is Aristo Bio-Tech and Lifescience IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Aristo Bio-Tech and Lifescience IPO.

  6. 6. When will Aristo Bio-Tech and Lifescience IPO allotment status?

    The Aristo Bio-Tech and Lifescience IPO allotment status will be available on or around January 24, 2023. The allotted shares will be credited in demat account by January 27, 2023. Visit Aristo Bio-Tech and Lifescience IPO allotment status to check.

  7. 7. When will Aristo Bio-Tech and Lifescience IPO list?

    The Aristo Bio-Tech and Lifescience IPO will list on Monday, January 30, 2023, at NSE SME.


1. Loya Hus     Link|January 11, 2023 12:02:12 PM
This company is also manufacturing for American, Chinese and Govt companies!
Seems promising.